$CLGN

CollPlant Biotechnologies Ltd

CIK:0001631487|SEC Filings

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Income Statement [Abstract]
Revenues	$ 2,371	$ 515	$ 10,959
Cost of revenues	835	1,625	1,991
Gross profit (loss)	1,536	(1,110)	8,968
Operating expenses:
Research and development	8,187	10,515	10,484
General, administrative and marketing	4,832	5,626	5,996
Total operating loss	(11,483)	(17,251)	(7,512)
Financial income (expenses), net	(6)	642	493
Net loss	$ (11,489)	$ (16,609)	$ (7,019)
Basic net loss per ordinary share (in Dollars per share)	$ (0.94)	$ (1.45)	$ (0.62)
Diluted net loss per ordinary share (in Dollars per share)	$ (0.94)	$ (1.45)	$ (0.62)
Weighted average number of ordinary shares used in computation of basic net loss per share (in Shares)	12,203,269	11,454,180	11,389,168
Weighted average number of ordinary shares used in computation of diluted net loss per share (in Shares)	12,203,269	11,454,180	11,389,168

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Cash flows from operating activities:
Net loss	$ (11,489)	$ (16,609)	$ (7,019)
Adjustments to reconcile net loss to net cash used in operating activities:
Loss on sale of property and equipment			18
Depreciation and amortization	912	1,038	1,102
Accrued interest	(15)	(11)	(28)
Share-based compensation to employees and consultants	999	1,719	1,937
Exchange differences on cash and cash equivalents and restricted cash	(80)	142	379
Changes in assets and liabilities:
Decrease (increase) in trade receivables	149	(150)	9
Decrease (increase) in inventories	(129)	280	749
Decrease (increase) in other receivables and prepaid expenses	210	(40)	150
Decrease in operating lease right-of-use assets	666	651	527
Decrease in trade payables	(260)	(110)	(153)
Decrease in operating lease liabilities	(336)	(650)	(638)
Increase in accrued liabilities and other payables	(46)	(353)	204
Net cash used in operating activities	(9,419)	(14,093)	(2,763)
Cash flows from investing activities:
Purchase of property and equipment	(28)	(483)	(954)
Investment in restricted deposits		(57)	(270)
Proceeds from sale of property and equipment	1	1	68
Net cash used in investing activities	(27)	(539)	(1,156)
Cash flows from financing activities:
Proceeds from issuance of shares and warrants less issuance expenses	3,102
Exercise of options and warrants into shares		9	1,108
Net cash provided by financing activities	3,102	9	1,108
Effect of exchange rate changes on cash and cash equivalents and restricted cash	26	(142)	(379)
Net decrease in cash and cash equivalents	(6,318)	(14,765)	(3,190)
Cash and cash equivalents at the beginning of the year	11,909	26,674	29,864
Cash and cash equivalents at the end of the year	5,591	11,909	26,674
Supplemental discloser of non-cash activities:
Right of use assets recognized with corresponding lease liabilities	101	572	886
Capitalization of Share-based compensation to inventory	4	6	33
Supplemental discloser of cash activities:
Cash paid during the year for taxes	$ 16	$ 62	$ 8

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Current assets:
Cash and cash equivalents	$ 5,591	$ 11,909
Restricted deposit	359	248
Trade receivables, net	1	150
Inventories	573	440
Other accounts receivable and prepaid expenses	223	433
Total current assets	6,747	13,180
Non-current assets:
Restricted deposit	76	118
Operating lease right-of-use assets	2,426	2,991
Property and equipment, net	1,463	2,290
Intangible assets, net	73	131
Total non-current assets	4,038	5,530
Total assets	10,785	18,710
Current liabilities:
Trade payables	610	870
Operating lease liabilities	814	806
Accrued liabilities and other payables	1,248	1,294
Total current liabilities	2,672	2,970
Non-current liabilities:
Operating lease liabilities	2,032	2,275
Total non-current liabilities	2,032	2,275
Total liabilities	4,704	5,245
Commitments and contingencies
Shareholders’ Equity:
Ordinary shares, NIS 1.5 par value - authorized: 30,000,000 ordinary shares as of December 31, 2025 and 2024; issued and outstanding: 12,803,006 and 11,454,512 ordinary shares as of December 31, 2025 and 2024, respectively	5,492	4,983
Additional paid in capital	126,397	122,801
Accumulated other comprehensive loss	(969)	(969)
Accumulated deficit	(124,839)	(113,350)
Total shareholders’ equity	6,081	13,465
Total liabilities and shareholders’ equity	$ 10,785	$ 18,710